Aller au contenu

Publications scientifiques

  • article Champagne PA, Bourassa M, Desjardins MP, Cloutier S, Demers C, Singbo NU, Néron H, Pelland-Marcotte MC

    Post-procedural bleeding rate and haemostatic treatment use for dental procedures before and after the implementation of a standardized protocol for people with inherited bleedi…

    Haemophilia 28 (5), 2022.

    DOI PUBMED
  • article Dubé E, Merlen C, Bonnefoy A, Gauthier J, Castilloux JF, Charlebois J, Cloutier S, Demers C, Sabapathy CA, St-Louis J, Vézina C, Warner M, Rivard GÉ

    Evaluation of anti-factor VIII antibodies in haemophilia A subjects switching products following a provincial tender

    Haemophilia 28 (1), 2022.

    DOI PUBMED
  • article Stimec J, Dover S, Pullenayegum E, Blanchette VS, Doria AS, Feldman BM, Carcao M, Rivard GE, Israels SJ, Chan AK, Steele M, Cloutier S, Klaassen RJ, Price VE, Sinha R, Laferriere N, Paradis E, Wu JKM, Babyn P

    Magnetic resonance imaging in boys with severe hemophilia A: Serial and end-of-study findings from the Canadian Hemophilia Primary Prophylaxis Study

    Res Pract Thromb Haemost 5 (7), 2021.

    DOI PUBMED
  • article Cheng J, Hashem MA, Barabé F, Cloutier S, Xi L, Raffeld M, Pittaluga S, Jaffe ES

    CCND1 Genomic Rearrangement as a Secondary Event in High Grade B-Cell Lymphoma

    Hemasphere 5 (1), 2021.

    DOI PUBMED
  • article Dubé E, Merlen C, Bonnefoy A, Gauthier J, Castilloux JF, Cloutier S, Demers C, Sabapathy CA, St-Louis J, Vézina C, Warner M, Rivard GÉ

    A prospective surveillance study in haemophilia B patients following a population switch to recombinant factor IX (nonacog gamma)

    Haemophilia 27 (4), 2021.

    DOI PUBMED
  • article Dover S, Blanchette VS, Wrathall D, Pullenayegum E, Kazandjian D, Song B, Hawes SA, Cloutier S, Rivard GE, Klaassen RJ, Paradis E, Laferriere N, Stain AM, Chan AK, Israels SJ, Sinha R, Steele M, Wu JKM, Feldman BM

    Hemophilia prophylaxis adherence and bleeding using a tailored, frequency-escalated approach: The Canadian Hemophilia Primary Prophylaxis Study

    Res Pract Thromb Haemost 4 (2), 2020.

    DOI PUBMED
  • article Greenblatt M, Cloutier S, Lemelin V

    Portal vein thrombosis in a patient known for congenital afibrinogenemia

    Haemophilia 26 (6), 2020.

    DOI PUBMED
  • article Vincent G, Richebourg S, Cloutier S, Fortin M, Jacob S, Amin-Hashem M

    Large B-Cell Lymphoma With IRF4 Rearrangement: From Theory to Practice

    AJSP Rev Rep 24 (5), 2019.

    DOI
  • article Mizrahi T, Doyon K, Dube E, Bonnefoy A, Warner M, Cloutier S, Demers C, Castilloux JF, Rivard GE, St-Louis J

    Relapse pattern and long-term outcomes in subjects with acquired haemophilia A

    Haemophilia 25 (2), 2019.

    DOI PUBMED
  • article Feldman BM, Rivard GE, Babyn P, Wu JKM, Steele M, Poon MC, Card RT, Israels SJ, Laferriere N, Gill K, Chan AK, Carcao M, Klaassen RJ, Cloutier S, Price VE, Dover S, Blanchette VS

    Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort

    Lancet Haematol 5 (6), 2018.

    DOI PUBMED
  • article Dube E, Bonnefoy A, Merlen C, Castilloux JF, Cloutier S, Demers C, Sabapathy CA, St-Louis J, Vezina C, Warner M, Rivard GE

    A prospective surveillance study of inhibitor development in haemophilia A patients following a population switch to a third-generation B-domain-deleted recombinant factor VIII

    Haemophilia 24 (2), 2018.

    DOI PUBMED
  • article St-Louis J, Urajnik DJ, Menard F, Cloutier S, Klaassen RJ, Ritchie B, Rivard GE, Warner M, Blanchette V, Young NL

    Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada

    BMC Hematol 16 2016.

    DOI PUBMED